Immune checkpoint inhibitor (ICI) paraneoplastic syndrome (PNS): management
Evidence-based neurology checklist on immune checkpoint inhibitor (ici) paraneoplastic syndrome (pns): management: Frequent antibodies Anti-Hu (ANNA1) Anti-Ma2 Anti-P/Q VGCC Other antibodies Cerebrospinal fluid (CSF) analysis Treatment
Frequent antibodies
- Anti-Hu (ANNA1)
- Anti-Ma2
- Anti-P/Q VGCC
Other antibodies
Cerebrospinal fluid (CSF) analysis
Treatment
References
- Zhang L, Fan S, Wang J, Ren H, Guan H. Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review. J Neurol 2025; 272:249.
- Farina A, Villagrán-García M, Vogrig A, et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 2024; 23:81-94.
- Farina A, Villagrán-García M, Ciano-Petersen NL, et al. Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 2022; 10:e200058.
- Mongay-Ochoa N, Vogrig A, Muñiz-Castrillo S, Honnorat J. Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment. J Neurol 2020; 267:2154-2156.
- Vogrig A, Fouret M, Joubert B, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 2019; 6:e604.
- And 1 more. Subscribe to see the full list
